Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients

Abstract The aim of our study was to assess whether large B-cell lymphoma (LBCL) in adolescents and young adults (AYA) should be considered as a clinocopathological entity, and to evaluate the prognostic value of age. Fifty-five patients aged > 15–30 years were fully matched to 365 adult patients aged 31–65 years. We found a high incidence of primary mediastinal thymic LBCL subtype (33% vs. 5%), while histological transformation was rare (2% vs. 14%). LBCL in AYA presented with a bulky mediastinal mass (51% vs. 21%), and the lactate dehydrogenase (LDH) value was significantly higher (73% vs. 54%). The complete response rate to chemotherapy was similar in the two groups. Five-year overall survival (OS) and event-free survival (EFS) of AYA were 73% and 68%, respectively. The matched-control analysis showed no difference for either OS or EFS. LBCL in AYA presents with some critical features which differ from those of older adults. However, the outcome is equivalent to that observed in older patients.

[1]  L. Brugières,et al.  Lymphoma in Adolescents and Young Adults. , 2016, Progress in tumor research.

[2]  James R. Anderson,et al.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report , 2013, Leukemia.

[3]  S. Perkins,et al.  Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. , 2013, Blood.

[4]  W. Wood,et al.  Malignant hematologic diseases in adolescents and young adults. , 2011, Blood.

[5]  S. Montoto,et al.  Transformation of indolent B-cell lymphomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Pfreundschuh,et al.  Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  W. Klapper,et al.  Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols , 2011, Leukemia.

[8]  W. Klapper,et al.  Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. B. Steele,et al.  Differences in non-Hodgkin lymphoma survival between young adults and children. , 2010, Archives of pediatrics & adolescent medicine.

[10]  J. Flynn,et al.  Lymphoma in adolescents and young adults. , 2009, Seminars in oncology.

[11]  John M. Walker,et al.  Cancer Epidemiology , 2009, Methods in Molecular Biology.

[12]  M. Pillon,et al.  Non Hodgkin lymphoma in adolescents and young adults , 2007 .

[13]  A. Bleyer,et al.  Cancer in 15- to 29-year-olds by primary site. , 2006, The oncologist.

[14]  W. Klapper,et al.  Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. , 2006, Blood.

[15]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[16]  A. Bleyer,et al.  Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. , 2006 .

[17]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[18]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Downing,et al.  Non-Hodgkin's lymphoma in childhood. , 1996, The New England journal of medicine.

[20]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[21]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[22]  Murphy Sb.  Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. , 1980 .

[23]  S. Murphy.  Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. , 1980, Seminars in oncology.